Immune Design (IMDZ) Tops Q3 EPS by 11c

Immune Design (NASDAQ: IMDZ) reported Q3 EPS of ($0.60), $0.11 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $1.73 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Independent Bank receives regulatory approval for HCB Financial acquisition